IGKV2D 40 | ENSG00000251039 | NCBI 28878

Details for: IGKV2D 40

Gene ID: 28878

Symbol: IGKV2D 40

Ensembl ID: ENSG00000251039

Description: immunoglobulin kappa variable 2D-40

Associated with

Adaptive immune system
(R-HSA-1280218)
Anti-inflammatory response favouring leishmania parasite infection
(R-HSA-9662851)
Antigen activates b cell receptor (bcr) leading to generation of second messengers
(R-HSA-983695)
Binding and uptake of ligands by scavenger receptors
(R-HSA-2173782)
Cd22 mediated bcr regulation
(R-HSA-5690714)
Cell surface interactions at the vascular wall
(R-HSA-202733)
Classical antibody-mediated complement activation
(R-HSA-173623)
Complement cascade
(R-HSA-166658)
Creation of c4 and c2 activators
(R-HSA-166786)
Disease
(R-HSA-1643685)
Fc epsilon receptor (fceri) signaling
(R-HSA-2454202)
Fceri mediated ca+2 mobilization
(R-HSA-2871809)
Fceri mediated mapk activation
(R-HSA-2871796)
Fceri mediated nf-kb activation
(R-HSA-2871837)
Fcgamma receptor (fcgr) dependent phagocytosis
(R-HSA-2029480)
Fcgr3a-mediated il10 synthesis
(R-HSA-9664323)
Fcgr3a-mediated phagocytosis
(R-HSA-9664422)
Fcgr activation
(R-HSA-2029481)
Hemostasis
(R-HSA-109582)
Immune system
(R-HSA-168256)
Immunoregulatory interactions between a lymphoid and a non-lymphoid cell
(R-HSA-198933)
Infectious disease
(R-HSA-5663205)
Initial triggering of complement
(R-HSA-166663)
Innate immune system
(R-HSA-168249)
Leishmania infection
(R-HSA-9658195)
Leishmania parasite growth and survival
(R-HSA-9664433)
Leishmania phagocytosis
(R-HSA-9664417)
Parasite infection
(R-HSA-9664407)
Parasitic infection pathways
(R-HSA-9824443)
Potential therapeutics for sars
(R-HSA-9679191)
Regulation of actin dynamics for phagocytic cup formation
(R-HSA-2029482)
Regulation of complement cascade
(R-HSA-977606)
Role of lat2/ntal/lab on calcium mobilization
(R-HSA-2730905)
Role of phospholipids in phagocytosis
(R-HSA-2029485)
Sars-cov infections
(R-HSA-9679506)
Scavenging of heme from plasma
(R-HSA-2168880)
Signaling by the b cell receptor (bcr)
(R-HSA-983705)
Vesicle-mediated transport
(R-HSA-5653656)
Viral infection pathways
(R-HSA-9824446)

Cells (max top 100)

(Cell Significance Index and respective Thresholds are uniquely calculated using our advanced thresholding algorithms to reveal cell-specific gene markers)

Cell Name: fraction A pre-pro B cell (CL0002045)
Fold Change: 0.1045
Cell Significance Index: 1.2400
Cell Name: megakaryocyte-erythroid progenitor cell (CL0000050)
Fold Change: 0.0966
Cell Significance Index: 1.3300
Cell Name: early T lineage precursor (CL0002425)
Fold Change: 0.0747
Cell Significance Index: 1.0900
Cell Name: neuron associated cell (CL0000095)
Fold Change: -0.0007
Cell Significance Index: -0.0300
Cell Name: immature innate lymphoid cell (CL0001082)
Fold Change: -0.0024
Cell Significance Index: -0.0300
Cell Name: L2/3-6 intratelencephalic projecting glutamatergic neuron (CL4023040)
Fold Change: -0.0027
Cell Significance Index: -0.5400
Cell Name: pericyte (CL0000669)
Fold Change: -0.0031
Cell Significance Index: -0.0400
Cell Name: fibroblast (CL0000057)
Fold Change: -0.0066
Cell Significance Index: -0.0600
Cell Name: lymphocyte (CL0000542)
Fold Change: -0.0070
Cell Significance Index: -0.1000
Cell Name: neutrophil progenitor cell (CL0000834)
Fold Change: -0.0073
Cell Significance Index: -0.2000
Cell Name: regular ventricular cardiac myocyte (CL0002131)
Fold Change: -0.0113
Cell Significance Index: -0.1500
Cell Name: endothelial cell of venule (CL1000414)
Fold Change: -0.0119
Cell Significance Index: -0.1400
Cell Name: mononuclear phagocyte (CL0000113)
Fold Change: -0.0120
Cell Significance Index: -0.1000
Cell Name: small intestine goblet cell (CL1000495)
Fold Change: -0.0125
Cell Significance Index: -0.4400
Cell Name: enterocyte of epithelium of small intestine (CL1000334)
Fold Change: -0.0128
Cell Significance Index: -0.3700
Cell Name: corticothalamic-projecting glutamatergic cortical neuron (CL4023013)
Fold Change: -0.0135
Cell Significance Index: -0.4300
Cell Name: neuron (CL0000540)
Fold Change: -0.0142
Cell Significance Index: -0.1300
Cell Name: nasal mucosa goblet cell (CL0002480)
Fold Change: -0.0159
Cell Significance Index: -0.1600
Cell Name: IgA plasma cell (CL0000987)
Fold Change: -0.0195
Cell Significance Index: -0.1300
Cell Name: B-1 B cell (CL0000819)
Fold Change: -0.0195
Cell Significance Index: -0.1700
Cell Name: transit amplifying cell of small intestine (CL0009012)
Fold Change: -0.0202
Cell Significance Index: -0.4200
Cell Name: common myeloid progenitor (CL0000049)
Fold Change: -0.0234
Cell Significance Index: -0.2800
Cell Name: megakaryocyte (CL0000556)
Fold Change: -0.0265
Cell Significance Index: -0.4300
Cell Name: vein endothelial cell (CL0002543)
Fold Change: -0.0277
Cell Significance Index: -0.3000
Cell Name: plasma cell (CL0000786)
Fold Change: -0.0318
Cell Significance Index: -0.3600
Cell Name: naive B cell (CL0000788)
Fold Change: -0.0318
Cell Significance Index: -0.3400
Cell Name: mast cell (CL0000097)
Fold Change: -0.0327
Cell Significance Index: -0.4300
Cell Name: B-1a B cell (CL0000820)
Fold Change: -0.0334
Cell Significance Index: -0.1800
Cell Name: endothelial cell of lymphatic vessel (CL0002138)
Fold Change: -0.0337
Cell Significance Index: -0.4100
Cell Name: medullary thymic epithelial cell (CL0002365)
Fold Change: -0.0338
Cell Significance Index: -0.3700
Cell Name: intestine goblet cell (CL0019031)
Fold Change: -0.0342
Cell Significance Index: -0.2900
Cell Name: elicited macrophage (CL0000861)
Fold Change: -0.0345
Cell Significance Index: -0.3000
Cell Name: pulmonary artery endothelial cell (CL1001568)
Fold Change: -0.0352
Cell Significance Index: -0.3800
Cell Name: lung macrophage (CL1001603)
Fold Change: -0.0358
Cell Significance Index: -0.3900
Cell Name: ciliated columnar cell of tracheobronchial tree (CL0002145)
Fold Change: -0.0359
Cell Significance Index: -0.3300
Cell Name: alveolar adventitial fibroblast (CL4028006)
Fold Change: -0.0360
Cell Significance Index: -0.4000
Cell Name: memory B cell (CL0000787)
Fold Change: -0.0362
Cell Significance Index: -0.3900
Cell Name: stem cell (CL0000034)
Fold Change: -0.0363
Cell Significance Index: -0.2600
Cell Name: precursor B cell (CL0000817)
Fold Change: -0.0371
Cell Significance Index: -0.4800
Cell Name: germinal center B cell (CL0000844)
Fold Change: -0.0373
Cell Significance Index: -0.2600
Cell Name: erythrocyte (CL0000232)
Fold Change: -0.0389
Cell Significance Index: -0.9900
Cell Name: endothelial cell (CL0000115)
Fold Change: -0.0391
Cell Significance Index: -0.4800
Cell Name: epithelial cell of proximal tubule (CL0002306)
Fold Change: -0.0396
Cell Significance Index: -0.3000
Cell Name: stromal cell (CL0000499)
Fold Change: -0.0401
Cell Significance Index: -0.4100
Cell Name: CD14-low, CD16-positive monocyte (CL0002396)
Fold Change: -0.0405
Cell Significance Index: -0.9800
Cell Name: T follicular helper cell (CL0002038)
Fold Change: -0.0406
Cell Significance Index: -0.4300
Cell Name: malignant cell (CL0001064)
Fold Change: -0.0408
Cell Significance Index: -0.2200
Cell Name: obsolete animal cell (CL0000548)
Fold Change: -0.0414
Cell Significance Index: -0.4200
Cell Name: conventional dendritic cell (CL0000990)
Fold Change: -0.0415
Cell Significance Index: -0.4900
Cell Name: tracheal goblet cell (CL1000329)
Fold Change: -0.0423
Cell Significance Index: -0.3500
Cell Name: transit amplifying cell (CL0009010)
Fold Change: -0.0427
Cell Significance Index: -0.4100
Cell Name: CD8-positive, alpha-beta memory T cell, CD45RO-positive (CL0001203)
Fold Change: -0.0444
Cell Significance Index: -0.4600
Cell Name: neutrophil (CL0000775)
Fold Change: -0.0456
Cell Significance Index: -0.5700
Cell Name: B-1b B cell (CL0000821)
Fold Change: -0.0458
Cell Significance Index: -0.2300
Cell Name: CD14-positive monocyte (CL0001054)
Fold Change: -0.0471
Cell Significance Index: -0.9200
Cell Name: pre-B-I cell (CL0000956)
Fold Change: -0.0478
Cell Significance Index: -0.2200
Cell Name: macrophage (CL0000235)
Fold Change: -0.0490
Cell Significance Index: -0.5000
Cell Name: epithelial cell (CL0000066)
Fold Change: -0.0512
Cell Significance Index: -0.5400
Cell Name: monocyte (CL0000576)
Fold Change: -0.0521
Cell Significance Index: -0.6000
Cell Name: B cell (CL0000236)
Fold Change: -0.0542
Cell Significance Index: -0.6400
Cell Name: T cell (CL0000084)
Fold Change: -0.0542
Cell Significance Index: -0.6400
Cell Name: B-2 B cell (CL0000822)
Fold Change: -0.0542
Cell Significance Index: -0.4800
Cell Name: plasmacytoid dendritic cell (CL0000784)
Fold Change: -0.0549
Cell Significance Index: -0.7200
Cell Name: CD14-positive, CD16-negative classical monocyte (CL0002057)
Fold Change: -0.0563
Cell Significance Index: -1.0400
Cell Name: natural killer cell (CL0000623)
Fold Change: -0.0578
Cell Significance Index: -0.6400
Cell Name: GABAergic neuron (CL0000617)
Fold Change: -0.0586
Cell Significance Index: -0.7400
Cell Name: IgG plasmablast (CL0000982)
Fold Change: -0.0630
Cell Significance Index: -0.5200
Cell Name: CD8-positive, alpha-beta memory T cell (CL0000909)
Fold Change: -0.0641
Cell Significance Index: -0.6500
Cell Name: mature NK T cell (CL0000814)
Fold Change: -0.0657
Cell Significance Index: -0.7400
Cell Name: innate lymphoid cell (CL0001065)
Fold Change: -0.0701
Cell Significance Index: -0.9000
Cell Name: alveolar macrophage (CL0000583)
Fold Change: -0.0709
Cell Significance Index: -0.6300
Cell Name: dendritic cell (CL0000451)
Fold Change: -0.0712
Cell Significance Index: -0.9300
Cell Name: small pre-B-II cell (CL0000954)
Fold Change: -0.0722
Cell Significance Index: -0.5800
Cell Name: regulatory T cell (CL0000815)
Fold Change: -0.0741
Cell Significance Index: -0.8600
Cell Name: non-classical monocyte (CL0000875)
Fold Change: -0.0741
Cell Significance Index: -0.8200
Cell Name: immature B cell (CL0000816)
Fold Change: -0.0761
Cell Significance Index: -0.7200
Cell Name: mucosal invariant T cell (CL0000940)
Fold Change: -0.0765
Cell Significance Index: -0.8800
Cell Name: class switched memory B cell (CL0000972)
Fold Change: -0.0774
Cell Significance Index: -0.6900
Cell Name: CD4-positive, alpha-beta T cell (CL0000624)
Fold Change: -0.0791
Cell Significance Index: -0.7400
Cell Name: CD1c-positive myeloid dendritic cell (CL0002399)
Fold Change: -0.0792
Cell Significance Index: -0.8200
Cell Name: classical monocyte (CL0000860)
Fold Change: -0.0795
Cell Significance Index: -0.7400
Cell Name: plasmablast (CL0000980)
Fold Change: -0.0797
Cell Significance Index: -0.7400
Cell Name: IgG plasma cell (CL0000985)
Fold Change: -0.0809
Cell Significance Index: -0.7400
Cell Name: blood cell (CL0000081)
Fold Change: -0.0833
Cell Significance Index: -0.7100
Cell Name: dendritic cell, human (CL0001056)
Fold Change: -0.0835
Cell Significance Index: -0.7700
Cell Name: type I NK T cell (CL0000921)
Fold Change: -0.0841
Cell Significance Index: -0.8200
Cell Name: platelet (CL0000233)
Fold Change: -0.0846
Cell Significance Index: -0.8700
Cell Name: CD8-positive, alpha-beta T cell (CL0000625)
Fold Change: -0.0865
Cell Significance Index: -0.8200
Cell Name: gamma-delta T cell (CL0000798)
Fold Change: -0.0892
Cell Significance Index: -0.8900
Cell Name: double-positive, alpha-beta thymocyte (CL0000809)
Fold Change: -0.0909
Cell Significance Index: -0.9800
Cell Name: CD16-positive, CD56-dim natural killer cell, human (CL0000939)
Fold Change: -0.0910
Cell Significance Index: -0.8100
Cell Name: effector memory CD4-positive, alpha-beta T cell (CL0000905)
Fold Change: -0.0919
Cell Significance Index: -0.8500
Cell Name: central memory CD4-positive, alpha-beta T cell (CL0000904)
Fold Change: -0.0926
Cell Significance Index: -0.8100
Cell Name: naive thymus-derived CD4-positive, alpha-beta T cell (CL0000895)
Fold Change: -0.0927
Cell Significance Index: -0.8000
Cell Name: IgA plasmablast (CL0000984)
Fold Change: -0.0939
Cell Significance Index: -0.7600
Cell Name: intermediate monocyte (CL0002393)
Fold Change: -0.0955
Cell Significance Index: -0.8900
Cell Name: activated CD8-positive, alpha-beta T cell (CL0000906)
Fold Change: -0.0969
Cell Significance Index: -0.8100
Cell Name: naive thymus-derived CD8-positive, alpha-beta T cell (CL0000900)
Fold Change: -0.0993
Cell Significance Index: -1.0000
Cell Name: unswitched memory B cell (CL0000970)
Fold Change: -0.0996
Cell Significance Index: -0.8900
Cell Name: CD8-positive, alpha-beta cytotoxic T cell (CL0000794)
Fold Change: -0.1013
Cell Significance Index: -0.8200

Cell ID: Standard Cell Ontology term used for mapping and comparing cells across experiments. Ensures consistency in analyzing cellular functions across tissues.
Fold Change: Represents the ratio of the current Cell Significance Index to the Cell Significance Index Threshold, indicating how much the gene expression has changed compared to a baseline.
Cell Significance Index: Reflects how strongly a gene is expressed in this specific cell.

Other Information

Description

**Key Characteristics** IGKV2D 40 is a kappa light chain variable region gene, which is a critical component of the B cell receptor (BCR) complex. The gene is characterized by its involvement in several key immune pathways, including: 1. **Complement activation**: IGKV2D 40 is involved in the classical pathway of complement activation, which is a critical mechanism for eliminating pathogens from the body. 2. **Phagocytosis**: The gene is also involved in phagocytosis, a process by which immune cells engulf and eliminate pathogens. 3. **Immune cell interactions**: IGKV2D 40 regulates interactions between immune cells, including T cells and dendritic cells, which is essential for coordinating an effective immune response. **Pathways and Functions** IGKV2D 40 is involved in several key pathways and functions, including: 1. **Adaptive immune system**: IGKV2D 40 is a component of the B cell receptor complex, which is critical for the adaptive immune response. 2. **Anti-inflammatory response**: The gene is involved in anti-inflammatory responses, particularly in the context of Leishmania parasite infection. 3. **Antigen presentation**: IGKV2D 40 is involved in antigen presentation, which is the process by which immune cells present antigens to T cells, triggering an immune response. 4. **Regulation of immune cell activity**: The gene regulates the activity of immune cells, including T cells and dendritic cells, which is essential for coordinating an effective immune response. **Clinical Significance** IGKV2D 40 has significant clinical implications, particularly in the context of Leishmania parasite infection. The gene's involvement in classical antibody-mediated complement activation and phagocytosis makes it a potential target for therapeutic interventions. Additionally, the gene's role in regulating immune cell interactions and anti-inflammatory responses makes it a potential target for the treatment of autoimmune diseases. Furthermore, IGKV2D 40's involvement in the adaptive immune system and antigen presentation makes it a potential target for the development of vaccines and immunotherapies. Overall, further research is needed to fully understand the clinical significance of IGKV2D 40 and its potential as a therapeutic target. **Implications for SARS and Leishmania Infections** IGKV2D 40's involvement in phagocytosis and antigen presentation makes it a potential target for the treatment of SARS and Leishmania infections. The gene's role in regulating immune cell interactions and anti-inflammatory responses also makes it a potential target for the treatment of autoimmune diseases associated with these infections. In the context of SARS, IGKV2D 40's involvement in phagocytosis and antigen presentation makes it a potential target for the development of therapeutic interventions. The gene's role in regulating immune cell interactions and anti-inflammatory responses also makes it a potential target for the treatment of autoimmune diseases associated with SARS. In the context of Leishmania infections, IGKV2D 40's involvement in classical antibody-mediated complement activation and phagocytosis makes it a potential target for the development of therapeutic interventions. The gene's role in regulating immune cell interactions and anti-inflammatory responses also makes it a potential target for the treatment of autoimmune diseases associated with Leishmania infections. **Potential Therapeutic Interventions** IGKV2D 40's involvement in various immune pathways makes it a potential target for the development of therapeutic interventions. Some potential therapeutic interventions include: 1. **Complement inhibitors**: Complement inhibitors could be used to target IGKV2D 40 and inhibit classical antibody-mediated complement activation. 2. **Phagocytosis inhibitors**: Phagocytosis inhibitors could be used to target IGKV2D 40 and inhibit phagocytosis. 3. **Immunomodulatory therapies**: Immunomodulatory therapies could be used to target IGKV2D 40 and regulate immune cell interactions and anti-inflammatory responses. 4. **Vaccines and immunotherapies**: Vaccines and immunotherapies could be developed to target IGKV2D 40 and stimulate an effective immune response against pathogens. Overall, further research is needed to fully understand the clinical significance of IGKV2D 40 and its potential as a therapeutic target.

Disclaimer: This summary is generated by an AI language model and may contain inaccuracies or hallucinations. However, it is cross-referenced with curated gene expression data from major biological sources. Please verify the information before use.

Database document:

This is a preview of the gene's schema. Only a few entries are kept for 'singleCellExpressions,' 'mRNAExpressions,' and other large data arrays for visualization purposes. You can zoom in with the mouse wheel for a closer view, and the text will adjust automatically if necessary. For the full schema, download it here.